Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The sodium/glucose cotransporter 2 inhibitor Empagliflozin inhibits long QT 3 late sodium currents in a mutation specific manner.

Journal of molecular and cellular cardiology - 1 Jan 2025

Lunsonga Lynn C, Fatehi Mohammad, Long Wentong, Barr Amy J, Gruber Brittany, Chattopadhyay Arkapravo, Barakat Khaled, Edwards Andrew G, Light Peter E

Abstract excerpt

BACKGROUND: Sodium/glucose cotransporter 2 inhibitors (SGLT2is) like empagliflozin have demonstrated cardioprotective effects in patients with or without diabetes. SGLT2is have been shown to selectively inhibit the late component of cardiac sodium current (late INa). Induction of late INa is the primary mechanism in the pathophysiology of congenital long QT syndrome type 3 (LQT3) gain-of-function mutations in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Action Potentials
Share to Benzhydryl Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucosides

Share to HEK293 Cells

Share to Long QT Syndrome

Share to Myocytes, Cardiac

Share to NAV1.5 Voltage-Gated Sodium Channel

Share to Sodium

Source

Identifiers

PMID: 39631445
DOI: 10.1016/j.yjmcc.2024.11.014

Genes

SCN5A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The sodium/glucose cotransporter 2 inhibitor Empagliflozin inhibits long QT 3 late sodium currents in a mutation specific manner.PMID 39631445Read ↗

The Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin Inhibits Long QT 3 Late Sodium Currents in a Mutation Specific MannerSemantic proximity Read ↗

The sodium/glucose cotransporter 2 inhibitor empagliflozin is a pharmacological chaperone of cardiac Na <sub>v</sub> 1.5 channelsSemantic proximity Read ↗

The efficacy of Ranolazine on E1784K is altered by temperature and calcium.Semantic proximity Read ↗

Exploring mutation specific beta blocker pharmacology of the pathogenic late sodium channel current from patient-specific pluripotent stem cell myocytes derived from long QT syndrome mutation carriers.Semantic proximity Read ↗

Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.Semantic proximity Read ↗

The Citrus Flavonoid Hesperetin Has an Inadequate Anti-Arrhythmic Profile in the ΔKPQ NaV1.5 Mutant of the Long QT Type 3 Syndrome.Semantic proximity Read ↗

Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome.Semantic proximity Read ↗

The role of late I Na in development of cardiac arrhythmias.Semantic proximity Read ↗

Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?Semantic proximity Read ↗

Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.Semantic proximity Read ↗

Intracellular calcium attenuates late current conducted by mutant human cardiac sodium channels.Semantic proximity Read ↗

Late cardiac sodium current can be assessed using automated patch-clampSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.